These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
67. The Use of Murine Models for Studying Mechanistic Insights of Genomic Instability in Multiple Myeloma. Vlummens P; De Veirman K; Menu E; De Bruyne E; Offner F; Vanderkerken K; Maes K Front Genet; 2019; 10():740. PubMed ID: 31475039 [TBL] [Abstract][Full Text] [Related]
68. Osteolytic disease in IL-6 and Myc dependent mouse model of human myeloma. Sun F; Cheng Y; Walsh SA; Acevedo MR; Jing X; Han SS; Pisano MD; Tomasson MH; Lichtenstein AK; Zhan F; Hari P; Janz S Haematologica; 2020 Mar; 105(3):e111-e115. PubMed ID: 31221780 [No Abstract] [Full Text] [Related]
69. What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between Bailly C; Gouard S; Guérard F; Chalopin B; Carlier T; Faivre-Chauvet A; Remaud-Le Saëc P; Bourgeois M; Chouin N; Rbah-Vidal L; Tripier R; Haddad F; Kraeber-Bodéré F; Bodet-Milin C; Chérel M Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31137758 [TBL] [Abstract][Full Text] [Related]
70. Immunotherapeutics in Multiple Myeloma: How Can Translational Mouse Models Help? Cooke RE; Koldej R; Ritchie D J Oncol; 2019; 2019():2186494. PubMed ID: 31093282 [TBL] [Abstract][Full Text] [Related]
71. Chronic intermittent hypoxia enhances disease progression in myeloma-resistant mice. Ali M; Kowkuntla S; Delloro DJ; Galambos C; Hathi D; Janz S; Shokeen M; Tripathi C; Xu H; Yuk J; Zhan F; Tomasson MH; Bates ML Am J Physiol Regul Integr Comp Physiol; 2019 May; 316(5):R678-R686. PubMed ID: 30892915 [TBL] [Abstract][Full Text] [Related]
73. Comparison of Immuno-PET of CD138 and PET imaging with Bailly C; Gouard S; Lacombe M; Remaud-Le Saëc P; Chalopin B; Bourgeois M; Chouin N; Tripier R; Halime Z; Haddad F; Faivre-Chauvet A; Kraeber-Bodéré F; Chérel M; Bodet-Milin C Oncotarget; 2018 Feb; 9(10):9061-9072. PubMed ID: 29507674 [TBL] [Abstract][Full Text] [Related]
74. Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine models. Liu B; Jones M; Kong L; Noel T; Jeng EK; Shi S; England CG; Alter S; Miller JS; Cai W; Rhode PR; Wong HC Cytokine; 2018 Jul; 107():105-112. PubMed ID: 29452720 [TBL] [Abstract][Full Text] [Related]
75. Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth. Delgado-Calle J; Anderson J; Cregor MD; Condon KW; Kuhstoss SA; Plotkin LI; Bellido T; Roodman GD Leukemia; 2017 Dec; 31(12):2686-2694. PubMed ID: 28529307 [TBL] [Abstract][Full Text] [Related]
76. Low intensity vibration mitigates tumor progression and protects bone quantity and quality in a murine model of myeloma. Pagnotti GM; Chan ME; Adler BJ; Shroyer KR; Rubin J; Bain SD; Rubin CT Bone; 2016 Sep; 90():69-79. PubMed ID: 27262776 [TBL] [Abstract][Full Text] [Related]
78. Perfusion Pressure Is a Critical Determinant of the Intratumoral Extravasation of Oncolytic Viruses. Miller A; Nace R; Ayala-Breton C C; Steele M; Bailey K; Peng KW; Russell SJ Mol Ther; 2016 Feb; 24(2):306-317. PubMed ID: 26647825 [TBL] [Abstract][Full Text] [Related]
79. Single-Dose Anti-CD138 Radioimmunotherapy: Bismuth-213 is More Efficient than Lutetium-177 for Treatment of Multiple Myeloma in a Preclinical Model. Fichou N; Gouard S; Maurel C; Barbet J; Ferrer L; Morgenstern A; Bruchertseifer F; Faivre-Chauvet A; Bigot-Corbel E; Davodeau F; Gaschet J; Chérel M Front Med (Lausanne); 2015; 2():76. PubMed ID: 26582128 [TBL] [Abstract][Full Text] [Related]
80. PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma. Noll JE; Vandyke K; Hewett DR; Mrozik KM; Bala RJ; Williams SA; Kok CH; Zannettino AC J Hematol Oncol; 2015 Oct; 8():106. PubMed ID: 26445238 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]